| Medical Drug Policy Name | Revised Criteria |
|---|---|
| Narsoplimab-wuug (Yartemlea®) "Notification"(PDF) | For initial criteria: Added requirement that the patient must be post-hematopoietic stem cell transplant for clarity. Removed requirement that diagnostic features must be from two or more time points within 14 days. Removed requirement that the patient must be classified as high-risk. Removed medical record documentation requirement from TA-TMA trigger evaluation. For continuation criteria: Added requirement that the patient has not experienced unacceptable toxicity with the requested agent. Duration of approval for both initial and continuation criteria was increased to 12 weeks, and the maximum units were updated to reflect the change. Other minor updates made throughout policy for clarity with no change to policy intent. Policy notification given 3/1/2026 for effective date 5/1/2026. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2026 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.